Ravi Mehrotra joined Flagship Pioneering in 2023. He works with  Flagship Growth companies to help maximize value creation opportunities for their bioplatforms.

Prior to joining Flagship, Ravi spent 20+ years in biotechnology equity research and investment banking and he has held various executive team operational roles. He was previously Senior Managing Director on Evercore ISI’s Biotech team and served in senior equity research roles at Credit Suisse and Cowen. Ravi started his career on Wall Street in 1997 at Bankers Trust-Alex Brown/Deutsche Bank.

Ravi developed a “macro-micro” approach to equity research encompassing thought leadership and industry analysis on a broad range of topics including bioparma R&D productivity, biotech business models, the gene and cell therapy revolution, and drug pricing. He was the number one ranked biotechnology analyst in both Institutional Investor and Extel surveys for multiple years and has been involved in over 200 IPO’s and financings globally.

Ravi holds a B.S. (Honors) and a Ph.D. in Biochemistry and Molecular Biology from The Wellcome Trust Center, Manchester University, UK.